Desjardins Global Asset Management Inc. Biomarin Pharmaceutical Inc Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 1,256 shares of BMRN stock, worth $82,468. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,256
Previous 1,312
4.27%
Holding current value
$82,468
Previous $116,000
4.31%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.49 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.27 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.24 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$913 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$689 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.2B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...